MAP2K7 and non-small cell lung carcinoma: Particularly, a new study is being conducted to investigate the role of hydroxyquinoline and binimetinib, a selective MEK inhibitor, in 29 patients with advanced KRAS-mutant NSCLC (NCT04735068).